TRAIL及TRAIL受体候选基因研究：与多发性硬化患者干扰素β治疗应答的关联
西班牙多发性硬化患者TRAIL/TRAIL受体基因54个SNP的候选基因研究数据，涉及干扰素β治疗应答与发病年龄关联。
基本信息
资源简介
该数据集来自一项针对西班牙多发性硬化（MS）患者的候选基因关联研究，旨在评估TRAIL及TRAIL受体基因（TRAIL、TRAILR-1、TRAILR-2、TRAILR-3、TRAILR-4）与发病年龄（AAO）及干扰素β（IFN beta）治疗临床应答的关系。研究在509例接受IFN beta治疗的MS患者中分析了54个SNP，并使用另外226例MS患者队列进行验证。结果显示TRAILR-1 rs20576-CC基因型患者对IFN beta治疗的临床应答优于携带A等位基因者（隐性模型 p=8.88×10−4，pc=0.048，OR=0.30），该SNP导致第228位谷氨酸变为丙氨酸（E228A）；TRAILR-2 rs1047275和TRAILR-4 rs7011559与发病年龄的关联未通过Bonferroni校正。研究还通过分子建模以及外周血单个核细胞亚群（单核细胞、CD4+和CD8+ T细胞）中TRAILR-1表达水平分析探索该变异的机制。数据内容为基因组SNP分型及临床应答相关数据，模态为基因组数据，可用于药物基因组学、生物标志物发现及多发性硬化治疗应答预测研究。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：Candidate Gene Study of <i>TRAIL</i> and <i>TRAIL Receptors</i>: Association with Response to Interferon Beta Therapy in Multiple Sclerosis Patients
- DOI：10.1371/journal.pone.0062540
- 发布日期：2013-04-29
- 文件数：4 个
- 文件总体积：285.18 KB
- 源站页面：https://plos.figshare.com/articles/dataset/Candidate_Gene_Study_of_TRAIL_and_TRAIL_Receptors_Association_with_Response_to_Interferon_Beta_Therapy_in_Multiple_Sclerosis_Patients/693200
命令行下载
curl -L -o "Table_S1.doc" "https://ndownloader.figshare.com/files/1047588"
curl -L -o "Table_S2.doc" "https://ndownloader.figshare.com/files/1047589"
curl -L -o "Table_S3.doc" "https://ndownloader.figshare.com/files/1047591"
curl -L -o "Table_S4.doc" "https://ndownloader.figshare.com/files/1047592"
文件清单
Table_S1.doc（115.71 KB）Table_S2.doc（106.50 KB）Table_S3.doc（30.72 KB）Table_S4.doc（32.26 KB）
文件总体积 285.18 KB（源站 API 实测）。
数据说明
TRAIL and TRAIL Receptor genes have been implicated in Multiple Sclerosis pathology as well as in the response to IFN beta therapy. The objective of our study was to evaluate the association of these genes in relation to the age at disease onset (AAO) and to the clinical response upon IFN beta treatment in Spanish MS patients. We carried out a candidate gene study of TRAIL, TRAILR-1, TRAILR-2, TRAILR-3 and TRAILR-4 genes. A total of 54 SNPs were analysed in 509 MS patients under IFN beta treatment, and an additional cohort of 226 MS patients was used to validate the results. Associations of rs1047275 in TRAILR-2 and rs7011559 in TRAILR-4 genes with AAO under an additive model did not withstand Bonferroni correction. In contrast, patients with the TRAILR-1 rs20576-CC genotype showed a better clinical response to IFN beta therapy compared with patients carrying the A-allele (recessive model: p = 8.88×10−4, pc = 0.048, OR = 0.30). This SNP resulted in a non synonymous substitution of Glutamic acid to Alanine in position 228 (E228A), a change previously associated with susceptibility to different cancer types and risk of metastases, suggesting a lack of functionality of TRAILR-1. In order to unravel how this amino acid change in TRAILR-1 would affect to death signal, we performed a molecular modelling with both alleles. Neither TRAIL binding sites in the receptor nor the expression levels of TRAILR-1 in peripheral blood mononuclear cell subsets (monocytes, CD4+ and CD8+ T cells) were modified, suggesting that this SNP may be altering the death signal by some other mechanism. These findings show a role for TRAILR-1 gene variations in the clinical outcome of IFN beta therapy that might have relevance as a biomarker to predict the response to IFN beta in MS.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.1371/journal.pone.0062540（source: https://plos.figshare.com/articles/dataset/Candidate_Gene_Study_of_TRAIL_and_TRAIL_Receptors_Association_with_Response_to_Interferon_Beta_Therapy_in_Multiple_Sclerosis_Patients/693200）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
